EcoDrugPlus

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSBGRG00000003319
Gene Symbol: MAPK11
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSBGRG00000007125
Gene Symbol: MAPK3
1 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSBGRG00000009935
Gene Symbol: MAPK8
1 Cross references
292 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSBGRG00000005703
Gene Symbol: MAPK9
1 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSBGRG00000024678
Gene Symbol: MAP2K1
1 Cross references
211 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSBGRG00000018429
Gene Symbol: MAP2K2
1 Cross references
269 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSBGRG00000020965
Gene Symbol: MAP3K10
1 Cross references
186 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSBGRG00000003502
Gene Symbol: MAP3K12
1 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSBGRG00000002802
Gene Symbol: MAP3K13
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSBGRG00000014827
Gene Symbol: MAP3K5
1 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSBGRG00000009390
Gene Symbol: MAP3K9
1 Cross references
195 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSBGRG00000012905
Gene Symbol: MAOB
1 Cross references
333 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).